ARCA biopharma, Inc.
(NASDAQ : ABIO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.95%176.301.2%$600.82m
GILDGilead Sciences, Inc.
0.62%68.020.9%$542.46m
BIIBBiogen Inc.
-0.06%280.401.2%$519.30m
CELGCelgene Corporation
-2.01%78.371.2%$513.71m
REGNRegeneron Pharmaceuticals, Inc.
-2.01%301.812.6%$316.79m
ALXNAlexion Pharmaceuticals, Inc.
-0.07%121.072.0%$253.26m
ILMNIllumina, Inc.
0.45%269.673.5%$244.32m
VRTXVertex Pharmaceuticals Incorporated
0.58%157.241.9%$236.54m
NKTRNektar Therapeutics
7.66%85.306.0%$212.18m
AAgilent Technologies, Inc.
1.15%64.321.5%$199.05m
INCYIncyte Corporation
1.79%67.832.5%$194.51m
SRPTSarepta Therapeutics, Inc.
1.78%93.4816.6%$131.29m
EXASExact Sciences Corporation
2.43%52.3625.5%$116.06m
BMRNBioMarin Pharmaceutical Inc.
0.51%88.884.4%$114.43m
ALNYAlnylam Pharmaceuticals, Inc
1.15%102.819.8%$103.66m

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, GencaroTM is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.